HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Beauty Farm Medical and Health Industry - Hard to Make Money Due to Industry Characteristics

ClouDr Group (9955.HK) -  “A Dark Horse” to Beat JD Health

Sino Biopharmaceutical (1177.HK) - The Positives and the Negatives

Alibaba Health Information Technology (241.HK) FY23H1 - Concerns Behind the Performance Turnaround

Pre-IPO ClouDr Group - The Logical Business Model Can Support Future Growth

China Makes U-Turn on COVID Policy - Here Are the Direct Impacts and Investment Opportunities

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

<ul>
<li>ClouDr released positive profit alert for 2022. We think ClouDr is in a virtuous circle based on its solid business model. It's a matter of time before ClouDr achieves breakeven. </li>
<li>As the number of hospitals/pharmacies newly deploying SaaS modules increases, and the existing B-end users continue to receive new patients,ClouDr is able to absorb new C-end users at low cost.</li>
<li>When more powerful competitors come in and carve up B-end market, ClouDr's long-term prospects may be uncertain, but its valuation shouldn't be much lower than Ping An Good Doctor. </li>
</ul>


ClouDr released positive profit alert for 2022. We think ClouDr is in a virtuous circle based on its solid business model. It's a matter of time before ClouDr achieves breakeven. 
As the number of hospitals/pharmacies newly deploying SaaS modules increases, and the existing B-end users continue to receive new patients,ClouDr is able to absorb new C-end users at low cost.
When more powerful competitors come in and carve up B-end market, ClouDr's long-term prospects may be uncertain, but its valuation shouldn't be much lower than Ping An Good Doctor. 


Ping An Healthcare and Technology (1833 HK)

ClouDr Group (9955.HK) - Positive Profit Alert for 2022, Thoughts on Business Model and the Concerns